Jazz Pharmaceuticals has acquired Chimerix Inc. for approximately $935 million in cash. Chimerix is now a wholly owned subsidiary of Jazz.

Ahead of a planned trial next month, Jazz Pharmaceuticals is moving to resolve antitrust allegations surrounding its key ...